PubMed Health⌕ Search

Biomedical subjects

R M Novak

Publications and source records attributed to R M Novak.

27 records · Page 2Linked to original sources
PubMed1990

Clinical pharmacokinetics of daptomycin.

Daptomycin is a new lipopeptide antibiotic for which preliminary pharmacokinetic data in adults have been limited to normal healthy volunteers and patients with renal insufficiency. We report the clinical pharmacokinetics of the first and fifth doses of iv daptomycin 150 mg (2 mg/kg) q24h in a 29-year-old man being treated for a gram-positive cellulitis and thrombophlebitis. Individual pharmacokinetic parameters yielded similar results during doses one and five. The pharmacokinetic profile observed in our patient did not markedly differ from data obtained from healthy volunteers.

Adult↗
PubMed1988

Use of thrombolytic therapy in axillary-subclavian vein thrombosis.

A case of axillary-subclavian vein thrombosis associated with effort is described (Paget-Schrötter syndrome). This patient was treated successfully with thrombolytic and anticoagulant therapy. Diagnosis and management of this rare clinical entity are discussed.

Axillary Vein↗
PubMed1988

Variable response to intravenous gamma-globulin therapy in a patient with autoimmune neutropenia, thrombocytopenia, and pemphigoid.

Intravenous high-dose gamma-globulin has been shown to be useful in some patients with immune thrombocytopenia or neutropenia. In the case we have reported, this regimen elevated the platelet but not the neutrophil count. This observation emphasizes the heterogeneity in patients with immune cytopenia, and shows that treatment outcome is likely to be influenced by a number of pathogenetic variables.

Aged↗
PubMedDate not supplied

Osteomyelitis caused by Rhodococcus equi in a renal transplant recipient.

We report the first case of osteomyelitis due to Rhodococcus equi, which occurred in a renal transplant patient. Infection with this organism is rare and usually causes a distinct clinical syndrome resembling pulmonary tuberculosis. We investigated by time-kill curve analysis various antimicrobial combinations for in vitro efficacy. The literature is briefly reviewed, and aspects of diagnosis and therapy are discussed.

Actinomycetales Infections↗
PubMedDate not supplied

The influence of stress management training in HIV disease.

A pretest-posttest design (with a 6-week wait-list control and a 6-month comparison group) was used to compare the effectiveness of a 6-week stress management training program with standard outpatient care for 45 men with HIV disease. Outcomes included stress levels, coping patterns, quality of life, psychological distress, illness-related uncertainty, and CD4+ T-lymphocyte levels. At 6 weeks, intervention was associated with increases in the emotional well-being dimension of quality of life. After 6 months, the intervention group had a relative decline in HIV-related intrusive thinking, indicating that stress management training may have buffered illness-related psychological distress over time.

Adult↗
PubMedDate not supplied

Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.

PURPOSE: The combination of abacavir + lamivudine (ABC+3TC) versus didanosine + stavudine (ddI+d4T), each combined with other classes of antiretrovirals (ARVs) in ARV-naive patients, was compared for the combined endpoint of time to plasma HIV RNA >50 copies/mL (at or after the 8-month visit) or death (primary endpoint) in a nested substudy of an ongoing multicenter randomized trial. METHOD: The substudy enrolled 182 patients; mean HIV RNA and CD4+ cell counts at baseline were 5.1 log10 copies/mL and 212 cells/mm3, respectively. RESULTS: After a median follow-up of 28 months, rates of primary endpoint were 57.2 and 67.8 per 100 person-years for the ABC+3TC and ddI+d4T groups (hazard ratio [HR]=0.81, 95% confidence interval [CI] 0.58-1.14, p=.23). CONCLUSION: There was a trend for treatments containing ABC+3TC to be better than treatments containing ddI+d4T with respect to HIV RNA decreases, CD4+ cell count increases, and tolerability.

Anti-HIV Agents↗
PubMedDate not supplied

Retrospective evaluation of therapies for Staphylococcus aureus endocarditis.

We retrospectively evaluated antiinfective therapy for methicillin-sensitive (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) endocarditis in 54 patients who had 57 treatment courses for the disease. Three treatments were assessed: 27 nafcillin-treated courses of MSSA endocarditis, 18 vancomycin-treated courses of MSSA endocarditis, and 11 vancomycin-treated courses of MRSA endocarditis. At baseline, patients with MSSA treated with vancomycin had more chronic conditions (p<0.01), a lower frequency of intravenous drug use (p<0.01), a lower hematocrit concentration (p<0.05), and a higher serum creatinine concentration (p<0.05) than the nafcillin group. Vancomycin-treated patients had a higher complication rate during therapy (p<0.05) and a longer duration in an intensive care unit (p<0.01) than the nafcillin group. The trend was for a higher complete response rate in the nafcillin group (74% vs 50%, p=0.12), but no difference in mortality (22% vs 28%, p=0.73). Patients with MRSA infection treated with vancomycin had higher mortality than those with MSSA who received that drug (55% vs 28%, p=0.24). Patients with vancomycin-treated MSSA endocarditis may have a poorer outcome than those who receive nafcillin, but this may be influenced by different or more severe clinical features.

Adult↗